Invesco Ltd. Buys 215,375 Shares of Altimmune, Inc. (NASDAQ:ALT)

Invesco Ltd. lifted its holdings in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 679.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 247,086 shares of the company's stock after purchasing an additional 215,375 shares during the quarter. Invesco Ltd. owned approximately 0.35% of Altimmune worth $1,781,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ALT. Virtu Financial LLC acquired a new stake in shares of Altimmune in the third quarter worth $674,000. Barclays PLC boosted its holdings in Altimmune by 93.0% during the third quarter. Barclays PLC now owns 155,741 shares of the company's stock valued at $956,000 after acquiring an additional 75,064 shares during the period. Wells Fargo & Company MN grew its position in shares of Altimmune by 69.3% in the fourth quarter. Wells Fargo & Company MN now owns 215,538 shares of the company's stock valued at $1,554,000 after purchasing an additional 88,209 shares during the last quarter. Stifel Financial Corp lifted its position in shares of Altimmune by 77.4% during the 3rd quarter. Stifel Financial Corp now owns 17,752 shares of the company's stock worth $109,000 after purchasing an additional 7,746 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in Altimmune during the 4th quarter valued at approximately $45,000. Institutional investors and hedge funds own 78.05% of the company's stock.

Wall Street Analysts Forecast Growth

ALT has been the subject of a number of research analyst reports. Stifel Nicolaus began coverage on Altimmune in a report on Wednesday, January 8th. They set a "buy" rating and a $18.00 price target for the company. William Blair reissued a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. Finally, HC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Altimmune in a report on Thursday, April 3rd. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Altimmune currently has a consensus rating of "Buy" and a consensus price target of $20.83.

Altimmune Price Performance

Shares of Altimmune stock traded up $0.60 during midday trading on Friday, hitting $5.77. 4,862,653 shares of the company were exchanged, compared to its average volume of 2,854,048. The firm has a 50 day simple moving average of $5.16 and a 200-day simple moving average of $6.65. The firm has a market cap of $444.37 million, a P/E ratio of -3.72 and a beta of 0.91. Altimmune, Inc. has a 52 week low of $3.55 and a 52 week high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Equities research analysts expect that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Insider Transactions at Altimmune

In other Altimmune news, CFO Gregory L. Weaver bought 10,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were bought at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the acquisition, the chief financial officer now owns 10,000 shares of the company's stock, valued at approximately $52,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 4.10% of the company's stock.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.